Exploring new treatments and outcomes in type 2 diabetes

Study identification

• EU PAS number:
  EUPAS40326
• Study ID:
  40327
• Official title and acronym:
  Exploring new treatments and outcomes in type 2 diabetes
• DARWIN EU® study:
  No
• Study countries:
  Denmark

  Finland

  Sweden

  United Kingdom
• Study description:
  This study aims to assess the effect of exposure to SGLT2i, GLP1RA and DPP4i drugs in type 2 diabetes. We will assess the effect of these medicines on continuous variable and clinical events in the Scottish Diabetes Register and then in meta-analysis with collaborators internationally. As such this will be a large, population-based observational study, which will look at both effectiveness and safety outcomes.
• Study status:
  Planned

Research institutions and networks

Institutions

University of Edinburgh (UofE)

United Kingdom

Steno Diabetes Center Denmark, University of Eastern Finland Finalnd, University of Gothenberg Sweden, University of Swansea United Kingdom

Study timelines

Date when funding contract was signed

Actual:01/08/2018

Study start date

Planned:01/08/2021

Date of final study report

Planned:01/08/2022

Sources of funding

Non-for-profit organisation (e.g. charity)

More details on funding

Diabetes UK

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable